Trusted Resource for Clinical Trials, Protocols & Progress
The FDA’s Pre-Submission program, often referred to as the Q-Submission or “Q-Sub” process, is a formal pathway that allows medical device sponsors to request feedback from the Center for Devices and Radiological Health (CDRH) or Center for Biologics Evaluation and Research (CBER) before submitting regulatory applications such as:
Click to read the full article.
Pre-submission meetings—whether Type A, B, or C—require precise coordination, documentation, and compliance with regulatory timelines. As the volume and complexity of submissions grow, the U.S. FDA has increasingly adopted electronic systems and tools to streamline interactions with sponsors. These e-tools enable faster meeting scheduling, better document handling, and improved transparency for both regulators and sponsors.
Click to read the full article.
Regulatory queries are formal requests from health authorities such as the FDA, EMA, Health Canada, or TGA, seeking clarification or additional information regarding a submitted application—be it an IND, NDA, BLA, ANDA, CTA, or marketing authorization. These queries can come in various forms: Information Requests (IRs), Deficiency Letters, 483s, or Clarification Requests. The way a sponsor addresses these queries often determines the fate of the submission—approval, delay, or rejection.
Click to read the full article.
Regulatory deficiency letters—such as Complete Response Letters (CRLs) from the FDA, List of Questions (LoQs) from EMA, or Clarifaxes from Health Canada—are formal communications issued when a health authority identifies gaps, deficiencies, or concerns in a submitted dossier. These letters signal that the application cannot proceed to approval unless the stated issues are resolved to the agency’s satisfaction.
Click to read the full article.
Regulatory authorities such as the FDA, EMA, or PMDA may issue deficiency letters, complete response letters (CRLs), or requests for clarification during the review of an IND, NDA, BLA, CTA, or ANDA. These communications often highlight gaps in the data, inconsistencies in the Common Technical Document (CTD), or procedural nonconformities. Without an accurate understanding of the underlying cause, responses may be superficial and risk rejection or prolonged review cycles.
Click to read the full article.
During regulatory review of applications such as INDs, NDAs, ANDAs, BLAs, CTAs, or MAAs, health authorities like the FDA, EMA, and Health Canada issue comments or questions that must be addressed before approval. These may arrive as formal deficiency letters (e.g., Complete Response Letter or List of Questions) or informal Information Requests (IRs).
Click to read the full article.
During the regulatory review of clinical trial applications, marketing authorizations, or variations, agencies such as the FDA, EMA, or PMDA may raise highly technical questions. These can relate to chemistry, manufacturing, and controls (CMC), clinical trial design, nonclinical data, statistical methodology, or pharmacovigilance strategies.
Click to read the full article.
When health authorities such as the FDA, EMA, MHRA, PMDA, or Health Canada issue questions during the review of a submission (IND, NDA, BLA, ANDA, CTA, MAA), they often trigger specific timelines for the sponsor to respond. These timelines vary depending on the agency, the type of communication, and the review pathway.
Click to read the full article.
During the lifecycle of regulatory submissions, sponsors and applicants often receive queries, comments, or deficiency letters from global health authorities such as the FDA (United States), EMA (Europe), PMDA (Japan), Health Canada, and others. These questions may pertain to the Chemistry, Manufacturing and Controls (CMC), Clinical, Nonclinical, or Labeling sections of a submission, and require well-documented responses to ensure a smooth review process.
Click to read the full article.
Regulatory submissions often hit roadblocks when agencies like the FDA, EMA, or PMDA request clarifications regarding data quality, study results, or dossier inconsistencies. How sponsors respond defines not only the speed of approval but also shapes their credibility with the authority.
Click to read the full article.
